Antihormonal therapy in breast cancer and mTOR inhibitors

被引：1

作者：

Heudel, Pierre-Etienne ^{[1
]}

Tredan, Olivier ^{[1
]}

Ray-Coquard, Isabelle ^{[1
]}

Treilleux, Isabelle ^{[1
]}

Guastalla, Jean-Paul ^{[1
]}

Bachelot, Thomas ^{[1
]}

机构：

[1] Ctr Leon Berard, F-69008 Lyon, France

来源：

BULLETIN DU CANCER | 2011年 / 98卷 / 12期

关键词：

metastatic breast cancer; hormonotherapy; mTOR inhibitors; PHASE-II; TEMSIROLIMUS; EVEROLIMUS; TAMOXIFEN; LETROZOLE; RAD001; COMBINATION; RESISTANCE; ACTIVATION;

D O I：

10.1684/bdc.2011.1496

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hormonal dependence of breast cancer has been known for a long time, yet about half of breast cancers with estrogen receptor will not respond to antihormonal therapy. Now, we know that this resistance may be related to a dysfunction of the estrogen pathway, or that of growth factors and particularly the pathway of cell activation PI3K/Akt/mTOR. Prevention of these different mechanisms of resistance could involve combination therapies such as anti-estrogens (SERMs, aromatase inhibitors) with inhibitors of the activity of growth factors that are particularly temsirolimus and everolimus for the activation pathway cell PI3K/Akt/mTOR.

引用

页码：1431 / 1437

页数：7

共 28 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Breast cancer with synchronous metastases: Trends in survival during a 14-year period [J].

Andre, F ;

Slimane, K ;

Bachelot, T ;

Dunant, A ;

Namer, M ;

Barrelier, A ;

Kabbaj, O ;

Spano, JP ;

Marsiglia, H ;

Rouzier, R ;

Delaloge, S ;

Spielmann, M .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3302-3308

[3] The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer:: Results of a phase I study with pharmacokinetics [J].

Awada, Ahmad ;

Cardoso, Fatima ;

Fontaine, Christel ;

Dirix, Luc ;

De Greve, Jacques ;

Sotiriou, Christos ;

Steinseifer, Jutta ;

Wouters, Carine ;

Tanaka, Chiaki ;

Zoellner, Ulrike ;

Tang, Pui ;

Piccart, Martine .

EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) :84-91

[4]

Bachelot T, 2010, SABCS

[5]

Baselga J, 2005, BREAST CANCER RES TR, V94, pS62

[6] Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer [J].

Baselga, Jose ;

Semiglazov, Vladimir ;

van Dam, Peter ;

Manikhas, Alexey ;

Bellet, Meritxell ;

Mayordomo, Jose ;

Campone, Mario ;

Kubista, Ernst ;

Greil, Richard ;

Bianchi, Giulia ;

Steinseifer, Jutta ;

Molloy, Betty ;

Tokaji, Erika ;

Gardner, Humphrey ;

Phillips, Penny ;

Stumm, Michael ;

Lane, Heidi A. ;

Dixon, J. Michael ;

Jonat, Walter ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2630-2637

[7] Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling [J].

Beeram, M. ;

Tan, Q.-T. N. ;

Tekmal, R. R. ;

Russell, D. ;

Middleton, A. ;

deGraffenried, L. A. .

ANNALS OF ONCOLOGY, 2007, 18 (08) :1323-1328

[8] Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells [J].

Boulay, A ;

Zumstein-Mecker, S ;

Stephan, C ;

Beuvink, I ;

Zilbermann, F ;

Haller, R ;

Tobler, S ;

Heusser, C ;

O'Reilly, T ;

Stolz, B ;

Marti, A ;

Thomas, G ;

Lane, HA .

CANCER RESEARCH, 2004, 64 (01) :252-261

[9] Inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer [J].

Boulay, A ;

Rudloff, J ;

Ye, JJ ;

Zumstein-Mecker, S ;

O'Reilly, T ;

Evans, DB ;

Chen, SU ;

Lane, HA .

CLINICAL CANCER RESEARCH, 2005, 11 (14) :5319-5328

[10] Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α -: A new model for anti-estrogen resistance [J].

Campbell, RA ;

Bhat-Nakshatri, P ;

Patel, NM ;

Constantinidou, D ;

Ali, S ;

Nakshatri, H .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) :9817-9824

← 1 2 3 →